Work

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

Year: 2015

Type: article

Source: The Journal of Infectious Diseases

DOI: 10.1093/infdis/jiv528

Authors: Kerri J. Penrose, Urvi M. Parikh, Kristen A. Hamanishi, Laura Else, David Back, Marta Boffito, Akil Jackson, John W. Mellors

Institutions: University of Pittsburgh, University of Liverpool, Chelsea and Westminster Hospital

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bill and Melinda Gates Foundation, Gilead Sciences

Award: University of Pittsburgh - to support bidirectional resistance profiling of TMC278, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and approved NNRTIs

OpenAlex ID: W2401613699

FWCI: 5.198

Cites: 17

Cited by: 42

Related to: 10